2016

UBIP was honored to be received by the President, who commended its innovative research and development achievements and outstanding contributions to healthcare.

UBIP was honored with the Top Ten Potential Enterprises and Innovation Design Award at the 13th Golden Torch Awards.

UBIP's innovative erythropoietin UB-852 and innovative interferon α8 UB-551 were awarded the National Brand Award for Best Product Category, as well as the Yushan Award, at the 13th National Brand Awards.

UBIP's anti-cancer targeted drug, B-Raf kinase inhibitor UB-941, has passed the Investigational New Drug (IND) review for human clinical trials by the U.S. Food and Drug Administration (FDA).

UBIP's B-Raf kinase inhibitor UB-941 was awarded the Annual Innovation Award at the 2016 Outstanding Biotechnology Industry Awards.

The Phase III clinical trial of human erythropoietin UB-851 has been granted financial support by the Ministry of Economic Affairs under its scientific and technological project.

The Biotechnology Development Center has granted authorization for the acquisition of the B-Raf kinase inhibitor anti-cancer targeted drug (UB-941).

UBIP held a presentation on its operations upon its listing on the emerging stock market.